p16 INK4A通过胆汁E2F1/FOXO1/IGF-1信号驱动高脂饮食喂养小鼠的非酒精性脂肪性肝病表型
研究在高脂/高胆固醇饮食喂养的野生型雄性小鼠中,于喂养第16周经尾静脉注射p16或对照Vivo Morpholino两次,评估p16抑制对NAFLD表型及胆汁E2F1/FOXO1/IGF-1信号的影响,并结合人正常、NAFLD和NASH肝样本及分离胆管细胞体外实验。结果显示p16 VM可减少胆管细胞和肝细胞p16,并降低小鼠NAFLD表型、胆管反应、胆汁衰老、血清代谢物及胆汁E2F1/FOXO1/IGF-1信号;人NAFLD/NASH中该信号升高并可被p16 VM阻断。结论认为减弱肝脏p16表达可能是改善NAFLD/NASH表型的治疗途径。
要点
- 高脂/高胆固醇饮食小鼠出现NAFLD表型、胆管反应、胆汁衰老及胆汁E2F1/FOXO1/IGF-1信号升高。
- p16 Vivo Morpholino处理降低胆管细胞和肝细胞p16,并减少上述小鼠指标。
- 人NAFLD/NASH中胆汁E2F1/FOXO1/IGF-1信号升高,可被p16 VM阻断。
核心结论
- 减弱肝脏p16表达可能是改善NAFLD/NASH表型的治疗途径。
研究设计与样本
- 4周龄野生型(C57BL/6J)雄性小鼠喂饲对照饮食或高脂/高胆固醇饮食,并于喂养第16周经尾静脉注射p16或对照Vivo Morpholino两次。
- 评估小鼠NAFLD表型、胆管反应与胆汁衰老、血清代谢物及胆汁E2F1/FOXO1/IGF-1信号。
- 评估人正常、NAFLD和NASH肝样本及分离胆管细胞(对照或p16 VM处理)的p16/E2F1/FOXO1/IGF-1信号。
主要发现
- 对照VM的高脂/高胆固醇饮食野生型小鼠NAFLD表型、胆管反应与胆汁衰老、血清代谢物及胆汁E2F1/FOXO1/IGF-1信号均增加。
- p16 VM处理降低胆管细胞和肝细胞p16,并减少上述小鼠指标。
- 人NAFLD/NASH中胆汁E2F1/FOXO1/IGF-1信号升高,p16 VM可阻断该信号。
- 体外p16 VM分别通过抑制RNA聚合酶II结合和E2F1在Foxo1位点的结合,降低胆汁E2f1和Foxo1转录。
- 体外抑制E2F1降低胆汁FOXO1。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: NAFLD is characterized by steatosis, hepatic inflammation, and fibrosis, which can develop into NASH. Patients with NAFLD/NASH have increased ductular reaction (DR) and biliary senescence. High fat/high cholesterol diet feeding increases biliary senescence, DR, and biliary insulin-like growth factor-1 (IGF-1) expression in mice. p16/IGF-1 converges with fork-head box transcription factor O1 (FOXO1) through E2F1. We evaluated p16 inhibition on NAFLD phenotypes and biliary E2F1/FOXO1/IGF-1 signaling. APPROACH AND RESULTS: 4-week wild-type (C57BL/6J) male mice were fed a control diet (CD) or high fat/high cholesterol diet and received either p16 or control Vivo Morpholino (VM) by tail vein injection 2× during the 16th week of feeding. We confirmed p16 knockdown and examined: (i) NAFLD phenotypes; (ii) DR and biliary senescence; (iii) serum metabolites; and (iv) biliary E2F1/FOXO1/IGF-1 signaling. Human normal, NAFLD, and NASH liver samples and isolated cholangiocytes treated with control or p16 VM were evaluated for p16/E2F1/FOXO1/IGF-1 signaling. p16 VM treatment reduced cholangiocyte and hepatocyte p16. In wild-type high fat/high cholesterol diet mice with control VM, there were increased (i) NAFLD phenotypes; (ii) DR and biliary senescence; (iii) serum metabolites; and (iv) biliary E2F1/FOXO1/IGF-1 signaling; however, p16 VM treatment reduced these parameters. Biliary E2F1/FOX-O1/IGF-1 signaling increased in human NAFLD/NASH but was blocked by p16 VM. In vitro , p16 VM reduced biliary E2f1 and Foxo1 transcription by inhibiting RNA pol II binding and E2F1 binding at the Foxo1 locus, respectively. Inhibition of E2F1 reduced biliary FOXO1 in vitro. CONCLUSION: Attenuating hepatic p16 expression may be a therapeutic approach for improving NAFLD/NASH phenotypes.
引用
- Kundu D, Kennedy L, Zhou T, et al. p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling. Hepatology. 2023. PMID: 36799449. doi:10.1097/HEP.0000000000000307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。